Payment overview · 2025
General Payments
$54,825.49
72 reported records · 5 companies
Healthcare provider profile · identity verified
Kay Ann Johnson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CINCINNATI, OH · NPI 1306802111
Verified facts
What the public records show
CMS Open Payments records show Kay Ann Johnson, M.D. received $54,825.49 in general payments during 2025 across 72 reported records.
Gilead Sciences, Inc. accounted for 99.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Descovy, Ozempic.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 362 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Descovy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $54,540.09 | 99.5% | 59 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $116.09 | 0.2% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $97.43 | 0.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.30 | 0.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.58 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $47,917.50 | 21 |
| Consulting Fee | $2,820.00 | 2 |
| Food and Beverage | $2,147.91 | 36 |
| Travel and Lodging | $1,940.08 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $21,533.84 | 23 | 2025 |
Source payment records
|
|||||
| Descovy Normalized: descovy |
Drug | Gilead Sciences, Inc. | $13,209.77 | 13 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $7,032.73 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $116.09 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $97.43 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.58 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 362 | exact normalized | Medicare Part D |
| Descovy descovy |
2025 | Descovy | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
362 | 42 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 572 | 168 |
| Levothyroxine Sodium | Levothyroxine Sodium | 424 | 114 |
| Losartan Potassium | Losartan Potassium | 416 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 391 | 114 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 362 | 42 |
| Lisinopril | Lisinopril | 313 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 71 |
| Gabapentin | Gabapentin | 265 | 60 |
| Omeprazole | Omeprazole | 243 | 68 |
| Zolpidem Tartrate | Zolpidem Tartrate | 228 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 207 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 199 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 50 |
| Trazodone Hcl | Trazodone Hcl | 169 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 148 | 41 |
| Lorazepam | Lorazepam | 145 | 35 |
| Simvastatin | Simvastatin | 144 | 45 |
| Alprazolam | Alprazolam | 140 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 132 | 41 |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 130 | 14 |
| Furosemide | Furosemide | 129 | 38 |
| Eliquis | Apixaban | 126 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 30 |
| Potassium Chloride | Potassium Chloride | 121 | 29 |
| Sertraline Hcl | Sertraline Hcl | 121 | 36 |
| Metformin Hcl | Metformin Hcl | 115 | 37 |
| Metformin Hcl Er | Metformin Hcl | 105 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 103 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 27 |
| Bupropion Xl | Bupropion Hcl | 99 | 22 |
| Clonazepam | Clonazepam | 98 | 17 |
| Glipizide Er | Glipizide | 96 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 94 | 11 |
| Synthroid | Levothyroxine Sodium | 93 | 28 |
| Azithromycin | Azithromycin | 90 | 76 |
| Buspirone Hcl | Buspirone Hcl | 88 | 20 |
| Ozempic | Semaglutide | 86 | 15 |
| Mirtazapine | Mirtazapine | 84 | 19 |
| Montelukast Sodium | Montelukast Sodium | 84 | 28 |
| Dovato | Dolutegravir Sodium/Lamivudine | 80 | suppressed |
| Januvia | Sitagliptin Phosphate | 79 | 13 |
| Famotidine | Famotidine | 76 | 23 |
| Atenolol | Atenolol | 75 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 26 |
| Temazepam | Temazepam | 75 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 24 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 73 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 72 | 23 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 71 | 11 |
| Methylprednisolone | Methylprednisolone | 67 | 58 |
| Valacyclovir | Valacyclovir Hcl | 66 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 17 |
| Alendronate Sodium | Alendronate Sodium | 60 | 15 |
| Carvedilol | Carvedilol | 60 | 17 |
| Meloxicam | Meloxicam | 59 | 26 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 59 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 14 |
| Spironolactone | Spironolactone | 55 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 48 |
| Estradiol | Estradiol | 51 | 17 |
| Descovy | Emtricitabine/Tenofov Alafenam | 50 | suppressed |
| Tivicay | Dolutegravir Sodium | 50 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 46 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 11 |
| Ibuprofen | Ibuprofen | 45 | 11 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 45 | suppressed |
| Isentress | Raltegravir Potassium | 44 | suppressed |
| Trulicity | Dulaglutide | 44 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 12 |
| Pregabalin | Pregabalin | 42 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 41 | 39 |
| Valsartan | Valsartan | 41 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 25 |
| Jardiance | Empagliflozin | 40 | suppressed |
| Prednisone | Prednisone | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 34 |
| Prezcobix | Darunavir/Cobicistat | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Allopurinol | Allopurinol | 36 | 12 |
| Celecoxib | Celecoxib | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Acyclovir | Acyclovir | 32 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 32 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 29 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | 12 |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 16 |
| Meclizine Hcl | Meclizine Hcl | 25 | 13 |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 19 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 11 |
| Ramipril | Ramipril | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Etravirine | Etravirine | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Nadolol | Nadolol | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 13 |
| Diazepam | Diazepam | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Edurant | Rilpivirine Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 12 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valtrex | Valacyclovir Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Naproxen | Naproxen | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $54,825.49 · 72 records | Gilead Sciences, Inc. | Biktarvy, Cologuard Collection Kit, Descovy, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Ozempic, Rybelsus, Yeztugo | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error